Ultragenyx Pharmaceutical (RARE) : $6.7 million worth of transactions were on upticks in Ultragenyx Pharmaceutical (RARE), compared to $5.76 million on downticks. The ratio between the two was 1.16, whereas, the net money flow stood at a healthy $0.94 million on Fridays session. The consistent buying on upticks in the stock accounted for $0.67million worth of trades. The total money flow into the stock stood at $0.67 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -1.73%. The stock was trading at $65.13, with a drop of $1.15 over the previous days close. The stock recorded -0.56% for the week.
The company Insiders own 10.1% of Ultragenyx Pharmaceutical shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -7.74% . Institutional Investors own 93.1% of Ultragenyx Pharmaceutical shares. During last six month period, the net percent change held by insiders has seen a change of -12.52%.
In a related news, The Securities and Exchange Commission has divulged that Kakkis Emil D, (President & CEO) of Ultragenyx Pharmaceutical Inc., had unloaded 20,000 shares at an average price of $67.75 in a transaction dated on August 15, 2016. The total value of the transaction was worth $1,355,000.
Ultragenyx Pharmaceutical (NASDAQ:RARE): stock was range-bound between the intraday low of $64.57 and the intraday high of $67.16 after having opened at $66.62 on Fridays session. The stock finally closed in the red at $66.62, a loss of -1.73%. The stock remained in the red for the whole trading day. The total traded volume was 353,003 shares. The stock failed to cross $67.16 in Fridays trading. The stocks closing price on Thursday was $66.275.
Ultragenyx Pharmaceutical (RARE) : During the past 4 weeks, traders have been relatively bearish on Ultragenyx Pharmaceutical (RARE), hence the stock is down -1.78% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.06% relative to the S&P 500. The 4-week change in the price of the stock is -1.91% and the stock has fallen -0.56% in the past 1 week.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).